Scientia CME – Staying Ahead of the Curve: Navigating the Rapid Advances in Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)

Details

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a demyelinating, autoimmune condition affecting the central nervous system. MOGAD is characterized by the presence of autoantibodies directed against the MOG protein located on the surface of myelin sheaths surrounding nerve fibers in the CNS. The disease course may be monophasic or relapsing, and a progressive course is extremely rare, making the mortality rate fairly low (2.1%) compared to other neuroinflammatory diseases. It is a relatively new addition to the category of demyelinating diseases, and approximately 10,000 cases of MOGAD are estimated within the U.S.

Topics Covered

Introductory content

• Epidemiology
• Disease characteristics, pathophysiology, clinical presentation
• Diagnostic methods and related challenges

Treatment

· Medications for acute, refractory, and maintenance, and the roles of:

• Methylprednisolone
• Rituximab, tocilizumab
• Azathioprine, mycophenolate mofetil
• IVIG

· Emerging therapies: agents targeting neonatal Fc receptor and IL-6

· Non-pharmacological interventions: physical rehabilitation for muscle weakness/gait impairment, reversible optic degeneration

· Ongoing challenges: difficulty predicting relapse based on patient presentation, identifying risk factors for relapse, relationships between medication timing and relapse probability 

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

• Summarize challenges related to the identification and health burden of MOGAD.
• Summarize the present and emerging therapies for MOGAD, and the differences between acute, refractory, and maintenance treatment plans.
• Formulate a treatment plan for a patient with MOGAD.

Target Audience

HCPs including but not limited to: neurology, internal medicine, and ophthalmology; physician assistants, nurse practitioners, and nurses who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with rare neurological diseases.

Additional credit info

CCME Activity #202962912

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.